Rationing Of Genzyme’s Myozyme In Europe Likely Through April Due To Supply Constraints
This article was originally published in The Pink Sheet Daily
Executive Summary
Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.